CIK 0001689375 · Accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entrada Therapeutics, Inc.
Sign in to watch- Ticker
- TRDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813983399
- Phone
- 857-305-1825
- Business address
- ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
- Former names
- CycloPorters, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,200,939
- in 8 filings
Net −$7,200,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-10 | Chapman Gina Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2026-06-10 | Thistle Mary Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2026-06-10 | Zeiher Bernhardt G Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2026-05-20 | Zeiher Bernhardt G Director | Purchase | +5,000 | $5.86 | $29K | 5,000 |
| 2026-05-04 | Sethuraman Natarajan President, Research & Develop. | Sale 10b5-1 | −25,907 | $15.39 | $399K | 216,317 |
| 2026-05-04 | Dowden Nathan J President & COO | Option exercise 10b5-1 | +15,000 | $1.74 | $26K | 213,588 |
| 2026-05-04 | Dowden Nathan J President & COO | Sale 10b5-1 | −15,000 | $15.33 | $230K | 198,588 |
| 2026-05-04 | Dowden Nathan J President & COO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,000 | 49,831 | ||
| 2026-04-01 | WENTWORTH KORY JAMES Chief Financial Officer | Sale 10b5-1 | −2,500 | $12.95 | $32K | 119,010 |
| 2026-03-10 | Dowden Nathan J President & COO | Sale 10b5-1 | −11,894 | $13.05 | $155K | 198,588 |
| 2026-03-10 | WENTWORTH KORY JAMES Chief Financial Officer | Sale 10b5-1 | −11,388 | $13.02 | $148K | 121,510 |
| 2026-03-09 | Dowden Nathan J President & COO | Sale 10b5-1 | −3,116 | $13.02 | $41K | 210,482 |
| 2026-03-09 | WENTWORTH KORY JAMES Chief Financial Officer | Sale 10b5-1 | −5,089 | $13.00 | $66K | 132,898 |
| 2026-03-04 | WENTWORTH KORY JAMES Chief Financial Officer | Sale 10b5-1 | −7,988 | $12.25 | $98K | 137,987 |
| 2026-03-03 | Sethuraman Natarajan President, Research & Develop. | Shares withheld for taxes | −7,577 | $11.76 | $89K | 242,224 |
| 2026-03-03 | Dowden Nathan J President & COO | Shares withheld for taxes | −14,038 | $11.76 | $165K | 213,598 |
| 2026-03-03 | WENTWORTH KORY JAMES Chief Financial Officer | Shares withheld for taxes | −5,712 | $11.76 | $67K | 145,975 |
| 2026-03-03 | Doshi Dipal CEO | Shares withheld for taxes | −19,181 | $11.76 | $225K | 526,014 |
| 2026-03-02 | Sethuraman Natarajan President, Research & Develop. | Shares withheld for taxes | −3,898 | $11.66 | $45K | 249,801 |
| 2026-03-02 | Dowden Nathan J President & COO | Shares withheld for taxes | −7,223 | $11.66 | $84K | 227,636 |
Page 3 of 12 · 230 trades